202 related articles for article (PubMed ID: 36189297)
1. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study.
Domínguez-Mozo MI; López-Lozano L; Pérez-Pérez S; García-Martínez Á; Torrejón MJ; Arroyo R; Álvarez-Lafuente R
Front Immunol; 2022; 13():991662. PubMed ID: 36189297
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort:
Domínguez-Mozo MI; González-Suárez I; Villar LM; Costa-Frossard L; Villarrubia N; Aladro Y; Pilo B; Montalbán X; Comabella M; Casanova-Peño I; Martínez-Ginés ML; García-Domínguez JM; García-Martínez MÁ; Arroyo R; Álvarez-Lafuente R
Front Immunol; 2023; 14():1248182. PubMed ID: 37841253
[TBL] [Abstract][Full Text] [Related]
3. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
4. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
5. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
Dominguez-Mozo MI; Galán V; Ramió-Torrentà L; Quiroga A; Quintana E; Villar LM; Costa-Frossard L; Fernández-Velasco JI; Villarrubia N; Garcia-Martinez MA; Arroyo R; Alvarez-Lafuente R
Front Immunol; 2024; 15():1384411. PubMed ID: 38911861
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis.
Waubant E; Mowry EM; Krupp L; Chitnis T; Yeh EA; Kuntz N; Ness J; Belman A; Milazzo M; Gorman M; Weinstock-Guttman B; Rodriguez M; James JA
Mult Scler; 2013 Jun; 19(7):891-5. PubMed ID: 23232601
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B
Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
[TBL] [Abstract][Full Text] [Related]
12. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis.
De Jager PL; Simon KC; Munger KL; Rioux JD; Hafler DA; Ascherio A
Neurology; 2008 Mar; 70(13 Pt 2):1113-8. PubMed ID: 18272866
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.
Wergeland S; Myhr KM; Løken-Amsrud KI; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Kvistad SS; Holmøy T; Riise T; Torkildsen Ø
Eur J Neurol; 2016 Jun; 23(6):1064-70. PubMed ID: 26998820
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis.
Csuka D; Simon D; Hóbor R; Uray K; Prohászka Z; Bánlaki Z; Jani PK; Szilágyi Á; Hudecz F; Rajczy K; Beke G; Boros Major A; Tordai A; Illés Z; Berki T; Czirják L; Füst G
Clin Exp Immunol; 2013 Mar; 171(3):255-62. PubMed ID: 23379431
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
16. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
17. Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile.
Chougule D; Nadkar M; Rajadhyaksha A; Pandit-Shende P; Surve P; Dawkar N; Khadilkar P; Patwardhan M; Kaveri S; Ghosh K; Pradhan V
J Med Virol; 2018 Mar; 90(3):559-563. PubMed ID: 28734074
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
Dominguez-Mozo MI; Perez-Perez S; Villar LM; Oliver-Martos B; Villarrubia N; Matesanz F; Costa-Frossard L; Pinto-Medel MJ; García-Sánchez MI; Ortega-Madueño I; Lopez-Lozano L; Garcia-Martinez A; Izquierdo G; Fernández Ó; Álvarez-Cermeño JC; Arroyo R; Alvarez-Lafuente R
Sci Rep; 2020 Aug; 10(1):14244. PubMed ID: 32859922
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
20. Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait.
Al-Temaimi R; Alroughani R; Jacob S; Al-Mulla F
J Neuroimmunol; 2015 Aug; 285():57-61. PubMed ID: 26198919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
